XML 71 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Parenthetical) (Detail) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred revenue, net of current $ 185,722 $ 186,801
Net unbilled co-development revenue 0 8,000
AstraZeneca Agreements [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred Revenue 175,646 171,516
Net unbilled co-development revenue 17,500 $ 9,100
AstraZeneca Agreements [Member] | U.S./RoW [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred revenue, net of current 158,200  
Deferred Revenue 175,600  
Net unbilled co-development revenue $ 17,500